VACCINE COMPOSITION CONTAINING TRANSFORMING GROWTH FACTOR ALPHA

• Main Authors: ALVAREZ ACOSTA, ANABEL, MULET SIERRA, AILLETTE, GUILLEN NIETO, GERARDO ENRIQUE, SANCHEZ RAMIREZ, BELINDA, GONZALEZ MARINELLO, GISELA MARIA, MENENDEZ MEDINA, TAMARA, PEREZ RODRIGUEZ, ROLANDO
• Format: Patent
• Language: English; French; German
• Published: 19.08.2009
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The present invention relates to the field of immunology and human medicine, in particular with a vaccine preparation able to provoke an immune-castration of self-TGFalpha. The object of this invention is to obtain a vaccine composition for the active immunotherapy of malignant tumors that depend of TGFalpha for its growth. As well as for the treatment of other TGFalpha depend diseases. Another important object of this invention is to obtain a vaccine composition containing a combination of TGFalpha with other EGF-R ligands, such as epidermal growth factor (EGF), able to inhibit the proliferation of tumors whose progression depends on these factors. In that way would be avoided the resistance generated by tumors vaccines containing each molecule for separate, developing tumorigenic phenotype that not depend on the growth factor used in the vaccination. These vaccine preparations are able to inhibit the proliferation of tumors with the characteristics mentioned before, and in this way to be useful in the treatment of malignant neoplasias. Therefore, the invention is also related with the field of specific active immunotherapy of cancer.